乔纳森·蒙森出售波士顿科学公司的5,000股股票（纽约证券交易所代码：BSX）股票|乔纳森_新浪财经

Boston Scientific Co. (NYSE:BSX – Get Rating) CAO Jonathan Monson sold 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $46.66, for a total transaction of $233,300.00. Following the sale, the chief accounting officer now directly owns 34,868 shares in the company, valued at approximately $1,626,940.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Boston Scientific Trading Up 0.9 %

Shares of NYSE BSX traded up $0.43 on Thursday, reaching $47.25. 4,590,807 shares of the company traded hands, compared to its average volume of 7,384,190. Boston Scientific Co. has a fifty-two week low of $34.98 and a fifty-two week high of $48.87. The company has a 50 day moving average of $46.53 and a 200 day moving average of $43.73. The company has a current ratio of 1.51, a quick ratio of 1.02 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $67.79 billion, a PE ratio of 104.05, a P/E/G ratio of 2.20 and a beta of 0.78.

Get

Boston Scientific

alerts:

Boston Scientific (NYSE:BSX – Get Rating) last issued its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.47 by ($0.02). Boston Scientific had a return on equity of 14.29% and a net margin of 5.50%. The firm had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.24 billion. During the same quarter in the previous year, the firm posted $0.45 EPS. The firm's revenue for the quarter was up 3.7% compared to the same quarter last year. On average, equities research analysts forecast that Boston Scientific Co. will post 1.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. International Assets Investment Management LLC purchased a new position in shares of Boston Scientific during the 1st quarter valued at approximately $54,000. Acadian Asset Management LLC acquired a new stake in Boston Scientific in the first quarter worth $35,000. Prudential PLC acquired a new stake in Boston Scientific in the first quarter worth $1,076,000. Cetera Investment Advisers increased its position in Boston Scientific by 24.0% in the first quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider's stock worth $1,275,000 after buying an additional 5,581 shares during the period. Finally, Sequoia Financial Advisors LLC acquired a new stake in Boston Scientific in the first quarter worth $230,000. Hedge funds and other institutional investors own 90.23% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research analyst reports. Barclays raised their price objective on shares of Boston Scientific from $49.00 to $53.00 in a report on Wednesday, January 4th. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $50.00 to $52.00 in a report on Wednesday, February 1st. Truist Financial lifted their price objective on shares of Boston Scientific from $50.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, December 20th. Needham & Company LLC lifted their price objective on shares of Boston Scientific from $48.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, February 2nd. Finally, Morgan Stanley boosted their target price on shares of Boston Scientific from $50.00 to $56.00 and gave the stock an "overweight" rating in a research report on Friday, January 6th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and an average target price of $51.50.

About Boston Scientific

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.